These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29523564)

  • 1. Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund.
    Sharma T; Choudhury M; Rejón-Parrilla JC; Jonsson P; Garner S
    BMJ Open; 2018 Mar; 8(3):e019777. PubMed ID: 29523564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research funding impact and priority setting - advancing universal access and quality healthcare research in Malaysia.
    Fun WH; Sararaks S; Tan EH; Tang KF; Chong DWQ; Low LL; Sapian RA; Ismail SA; Govind SK; Mahmud SH; Murad S
    BMC Health Serv Res; 2019 Apr; 19(1):248. PubMed ID: 31018843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
    Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
    Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying research needs for improving health care.
    Chang SM; Carey TS; Kato EU; Guise JM; Sanders GD
    Ann Intern Med; 2012 Sep; 157(6):439-45. PubMed ID: 22847017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of NIHR HTA Programme funded research on NICE clinical guidelines: a retrospective cohort.
    Turner S; Bhurke S; Cook A
    Health Res Policy Syst; 2015 Aug; 13():37. PubMed ID: 26297470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTOCOL: Barriers and facilitators to stakeholder engagement in health guideline development: A qualitative evidence synthesis.
    Magwood O; Riddle A; Petkovic J; Lytvyn L; Khabsa J; Atwere P; Akl EA; Campbell P; Welch V; Smith M; Mustafa RA; Limburg H; Dans LF; Skoetz N; Grant S; Concannon T; Tugwell P
    Campbell Syst Rev; 2022 Jun; 18(2):e1237. PubMed ID: 36911345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 12. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-informed evidence-making.
    Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
    J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving outcomes for people in mental health crisis: a rapid synthesis of the evidence for available models of care.
    Paton F; Wright K; Ayre N; Dare C; Johnson S; Lloyd-Evans B; Simpson A; Webber M; Meader N
    Health Technol Assess; 2016 Jan; 20(3):1-162. PubMed ID: 26771169
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.